The Cancer Stage Shifting Initiative: Registry and Biorepository to Research and Address Health Disparities in Cancer Care
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Cancer, Cancer Comorbidities. Basic parameters: from 35 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The goal of this observational study is to establish a patient registry and a biorepository (sample collection and storage) to investigate health disparities, access, and barriers to cancer screening and early detection technologies. The registry and biorepository will serve as a resource to support Cancer Early Detection (CED) screenings and future research focused on communities at increased risk for cancer. The study seeks to address: •Barriers and disparities in cancer prevention, screening, and treatment, particularly in historically underrepresented populations. Participants will: * Attend a minimum of five clinic visits over a five-year period for scheduled annual assessments while actively enrolled in the study. * Complete questionnaires at each visit that collect information on their medical history, cancer history, and family cancer history. * Allow relevant health information from their electronic health records (EHR) to be collected and reviewed. * Provide blood, saliva, and stool samples for research purposes. * Enter a long-term follow-up period for an additional five years.
Primary outcome measures
- Establish a patient registry [Time frame: From enrollment to the end of follow up at 10 years.]
Secondary outcome measures (1)
- Establish a biorepository [Time frame: From enrollment to the end of follow up at 10 years.]
Eligibility criteria
Registry
Inclusion criteria
- Adults 35 years and older.
- Participant provides written informed consent prior to initiation of any study procedures.
- Participant understands the purpose and procedures of the study.
- Participant agrees that demographic data, medical history, and social determinants of health on the enrollment questionnaires can be used for research purposes.
- Participant agrees to the release and review of their electronic medical record.
- Participant agrees to be followed for the duration outlined in this protocol.
Biorepository
- Participant is able, in the investigator's professional opinion, to provide up to 100 mLs of whole blood at the Screening Visit and at the Interim Visits.
- Participant is a healthy, nonpregnant adult.
- Participant weighs at least 110 pounds.
- Participant has negative viral test results.
Exclusion criteria
Registry
- Any medical or mental condition that would interfere with the subjects' ability to willingly give written informed consent.
- Participants who are unable to understand the study protocol or unable to give informed consent.
- Participants under the age of 35 at the time of enrollment.
Biorepository
- Women of childbearing age that think they may be pregnant or are planning to get pregnant within the study timeframe.
- Participants who weigh under 110 pounds.
- Participants who, in the opinion of the investigator, are unable to provide biospecimen samples.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
United States · 2 centers
- Life in 3D Health Services — Flint
- Grace Clinic — Houston
Identifiers
NCT: NCT07461493 · CSSI-ED-25